Free Trial
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free TELA Stock Alerts

TELA Bio (TELA) Competitors

TELA Bio logo
$0.88 0.00 (-0.10%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$0.88 0.00 (-0.01%)
As of 06/5/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TELA vs. HYPR, CVRX, SNWV, MBOT, and NNOX

Should you buy TELA Bio stock or one of its competitors? MarketBeat compares TELA Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TELA Bio include Hyperfine (HYPR), CVRx (CVRX), Sanuwave Health (SNWV), Microbot Medical (MBOT), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry.

How does TELA Bio compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Hyperfine has higher earnings, but lower revenue than TELA Bio. Hyperfine is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hyperfine$15.33M8.94-$35.57M-$0.41N/A
TELA Bio$80.28M0.49-$38.83M-$0.79N/A

Hyperfine has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Comparatively, 4.7% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TELA Bio has a net margin of -49.30% compared to Hyperfine's net margin of -226.88%. Hyperfine's return on equity of -98.83% beat TELA Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Hyperfine-226.88% -98.83% -67.09%
TELA Bio -49.30%-1,320.81%-55.83%

Hyperfine currently has a consensus price target of $1.78, indicating a potential upside of 29.23%. TELA Bio has a consensus price target of $2.20, indicating a potential upside of 149.97%. Given TELA Bio's stronger consensus rating and higher possible upside, analysts plainly believe TELA Bio is more favorable than Hyperfine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperfine
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
TELA Bio
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Hyperfine had 2 more articles in the media than TELA Bio. MarketBeat recorded 2 mentions for Hyperfine and 0 mentions for TELA Bio. Hyperfine's average media sentiment score of 0.42 beat TELA Bio's score of 0.00 indicating that Hyperfine is being referred to more favorably in the media.

Company Overall Sentiment
Hyperfine Neutral
TELA Bio Neutral

Summary

Hyperfine beats TELA Bio on 8 of the 15 factors compared between the two stocks.

How does TELA Bio compare to CVRx?

TELA Bio (NASDAQ:TELA) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

TELA Bio has higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TELA Bio$80.28M0.49-$38.83M-$0.79N/A
CVRx$59.07M2.42-$53.31M-$2.02N/A

TELA Bio has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, CVRx has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 4.7% of TELA Bio shares are held by insiders. Comparatively, 13.9% of CVRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TELA Bio has a net margin of -49.30% compared to CVRx's net margin of -89.14%. CVRx's return on equity of -120.76% beat TELA Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
TELA Bio-49.30% -1,320.81% -55.83%
CVRx -89.14%-120.76%-48.38%

TELA Bio currently has a consensus target price of $2.20, indicating a potential upside of 149.97%. CVRx has a consensus target price of $11.50, indicating a potential upside of 113.75%. Given TELA Bio's higher probable upside, research analysts clearly believe TELA Bio is more favorable than CVRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TELA Bio
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
CVRx
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, CVRx had 1 more articles in the media than TELA Bio. MarketBeat recorded 1 mentions for CVRx and 0 mentions for TELA Bio. TELA Bio's average media sentiment score of 0.00 equaled CVRx'saverage media sentiment score.

Company Overall Sentiment
TELA Bio Neutral
CVRx Neutral

Summary

TELA Bio beats CVRx on 9 of the 16 factors compared between the two stocks.

How does TELA Bio compare to Sanuwave Health?

TELA Bio (NASDAQ:TELA) and Sanuwave Health (NASDAQ:SNWV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Sanuwave Health has a net margin of 35.96% compared to TELA Bio's net margin of -49.30%. Sanuwave Health's return on equity of -450.56% beat TELA Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
TELA Bio-49.30% -1,320.81% -55.83%
Sanuwave Health 35.96%-450.56%44.87%

TELA Bio currently has a consensus target price of $2.20, indicating a potential upside of 149.97%. Sanuwave Health has a consensus target price of $51.00, indicating a potential upside of 245.53%. Given Sanuwave Health's stronger consensus rating and higher probable upside, analysts clearly believe Sanuwave Health is more favorable than TELA Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TELA Bio
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Sanuwave Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, TELA Bio's average media sentiment score of 0.00 equaled Sanuwave Health'saverage media sentiment score.

Company Overall Sentiment
TELA Bio Neutral
Sanuwave Health Neutral

TELA Bio has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 4.7% of TELA Bio shares are held by insiders. Comparatively, 14.4% of Sanuwave Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sanuwave Health has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TELA Bio$80.28M0.49-$38.83M-$0.79N/A
Sanuwave Health$44.34M2.86$11.81M$0.3344.73

Summary

Sanuwave Health beats TELA Bio on 12 of the 15 factors compared between the two stocks.

How does TELA Bio compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Microbot Medical has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Microbot Medical's return on equity of -21.84% beat TELA Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbot MedicalN/A -21.84% -20.71%
TELA Bio -49.30%-1,320.81%-55.83%

Microbot Medical currently has a consensus target price of $6.63, indicating a potential upside of 260.05%. TELA Bio has a consensus target price of $2.20, indicating a potential upside of 149.97%. Given Microbot Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Microbot Medical is more favorable than TELA Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
TELA Bio
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Microbot Medical had 1 more articles in the media than TELA Bio. MarketBeat recorded 1 mentions for Microbot Medical and 0 mentions for TELA Bio. Microbot Medical's average media sentiment score of 0.00 equaled TELA Bio'saverage media sentiment score.

Company Overall Sentiment
Microbot Medical Neutral
TELA Bio Neutral

Microbot Medical has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by company insiders. Comparatively, 4.7% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Microbot Medical has higher earnings, but lower revenue than TELA Bio. Microbot Medical is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbot Medical$105K1,176.99-$13.14M-$0.26N/A
TELA Bio$80.28M0.49-$38.83M-$0.79N/A

Summary

Microbot Medical beats TELA Bio on 11 of the 16 factors compared between the two stocks.

How does TELA Bio compare to Nano-X Imaging?

TELA Bio (NASDAQ:TELA) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

TELA Bio has a net margin of -49.30% compared to Nano-X Imaging's net margin of -790.87%. Nano-X Imaging's return on equity of -64.65% beat TELA Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
TELA Bio-49.30% -1,320.81% -55.83%
Nano-X Imaging -790.87%-64.65%-57.27%

In the previous week, Nano-X Imaging had 2 more articles in the media than TELA Bio. MarketBeat recorded 2 mentions for Nano-X Imaging and 0 mentions for TELA Bio. TELA Bio's average media sentiment score of 0.00 equaled Nano-X Imaging'saverage media sentiment score.

Company Overall Sentiment
TELA Bio Neutral
Nano-X Imaging Neutral

TELA Bio has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TELA Bio$80.28M0.49-$38.83M-$0.79N/A
Nano-X Imaging$13.02M10.32-$75.02M-$1.59N/A

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 4.7% of TELA Bio shares are held by insiders. Comparatively, 7.7% of Nano-X Imaging shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TELA Bio has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

TELA Bio presently has a consensus price target of $2.20, indicating a potential upside of 149.97%. Nano-X Imaging has a consensus price target of $5.00, indicating a potential upside of 159.07%. Given Nano-X Imaging's stronger consensus rating and higher probable upside, analysts plainly believe Nano-X Imaging is more favorable than TELA Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TELA Bio
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Nano-X Imaging
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
3 Strong Buy rating(s)
2.83

Summary

TELA Bio beats Nano-X Imaging on 9 of the 16 factors compared between the two stocks.

Get TELA Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TELA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TELA vs. The Competition

Export
MetricTELA BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$39.44M$3.35B$6.64B$12.42B
Dividend YieldN/A2.33%2.68%5.34%
P/E Ratio-1.1119.0223.8423.63
Price / Sales0.49308.79577.54137.68
Price / CashN/A116.1242.4257.17
Price / Book5.506.519.736.35
Net Income-$38.83M$24.19M$3.57B$337.59M
7 Day Performance-9.27%-6.96%-1.26%-2.51%
1 Month Performance-11.10%-4.27%0.82%-0.69%
1 Year Performance-53.43%36.81%24.09%25.37%

TELA Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TELA
TELA Bio
2.7646 of 5 stars		$0.88
-0.1%		$2.20
+150.0%		-54.9%$39.44M$80.28MN/A120
HYPR
Hyperfine
3.0431 of 5 stars		$1.54
+1.0%		$1.78
+16.2%		+59.8%$154.86M$11.40MN/A190
CVRX
CVRx
2.0004 of 5 stars		$5.44
+0.1%		$11.50
+111.6%		-16.7%$148.07M$56.65MN/A160
SNWV
Sanuwave Health
1.6477 of 5 stars		$15.32
-3.4%		$51.00
+233.0%		-46.9%$141.62M$44.05M47.5440
MBOT
Microbot Medical
2.1539 of 5 stars		$1.99
+0.3%		$7.50
+277.8%		-31.3%$136.35MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TELA) was last updated on 6/6/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
In 30 days, you'll wish you'd read this email
A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...
Behind the Markets | Sponsoredtc pixel
BUY THIS: Claim a backdoor stake in SpaceX before June 12
Marc Chaikin, the Wall Street veteran who spotted Nvidia before a 45,000% run, says there's a simple trade ava...
Chaikin Analytics | Sponsoredtc pixel
How to get into the SpaceX IPO before June 12
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
This won't stay free
A few times a year, Bill Poulos makes his book Simple Options Trading for Beginners available at no cost. It n...
Profits Run | Sponsoredtc pixel